Dechert Advises Zyla Life Sciences in Merger with Assertio Therapeutics

March 17, 2020

Dechert is advising Zyla Life Sciences in its definitive merger agreement with Assertio Therapeutics, Inc., announced March 16. The merger will create a leading commercial pharmaceutical company with neurology, inflammation and pain products. The combined company will have a leading portfolio of branded non-steroidal anti-inflammatory drugs (NSAIDs) commonly used by neurologists, orthopedic surgeons, internists, women's health providers, podiatrists and pain care specialists. The deal is currently expected to close in the second quarter of 2020, subject to approval by Assertio stockholders and by Zyla stockholders, and the satisfaction of other customary closing conditions.

The Dechert team advising Zyla Life Sciences includes corporate partner David Rosenthal and associates John Alessi and Philip Treesh; finance partner Sarah Gelb; benefits partner Eric Rubin and associate Lany Villalobos; tax partner Josh Milgrim and associate Reuven Rosen; restructuring partner Shmuel Vasser; and intellectual property partner Thomas Rayski. 

About Dechert

Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.